New drug trial aims to strengthen bones in kids with rare genetic disorder
NCT ID NCT06079359
Summary
This study is testing whether an experimental drug called ALXN1850 can improve bone health and physical abilities in children aged 2-12 with hypophosphatasia, a rare genetic condition that weakens bones. Participants receive either the drug or a placebo through injections under the skin for about 6 months. Researchers measure changes in bone X-rays, walking distance, and motor skills to see if the treatment helps.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Kansas City, Missouri, 64108, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Parkville, 3052, Australia
-
Research Site
Brussels, 1020, Belgium
-
Research Site
Brasília, 71625-009, Brazil
-
Research Site
Porto Alegre, 90610-261, Brazil
-
Research Site
Recife, 50740-465, Brazil
-
Research Site
Salvador, 40050-410, Brazil
-
Research Site
São Paulo, 01409-902, Brazil
-
Research Site
São Paulo, 05403-900, Brazil
-
Research Site
Calgary, Alberta, T2E 7Z4, Canada
-
Research Site
Winnepeg, Manitoba, R3E 3P4, Canada
-
Research Site
Beijing, 100045, China
-
Research Site
Guangzhou, 510623, China
-
Research Site
Shanghai, 2000127, China
-
Research Site
Shenzhen, 518053, China
-
Research Site
Helsinki, 00290, Finland
-
Research Site
Ashkelon, 7830604, Israel
-
Research Site
Chihuahua City, 31238, Mexico
-
Research Site
Lodz, 93-338, Poland
-
Research Site
Bucharest, 011863, Romania
-
Research Site
Madrid, 28046, Spain
-
Research Site
Vitoria-Gasteiz, 01009, Spain
-
Research Site
Stockholm, 17176, Sweden
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Bursa, 16059, Turkey (Türkiye)
-
Research Site
Erzurum, 25240, Turkey (Türkiye)
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Birmingham, B4 6NH, United Kingdom
Conditions
Explore the condition pages connected to this study.